Aprea Therapeutics Inc

This management proposal requests shareholder approval to amend the Company’s certificate of incorporation to authorize the Board to implement a reverse stock split of common stock at a ratio the Board may choose within a 1-for-3 to 1-for-8 range, with fractional shares rounded up. Management frames the split primarily as a tool to increase the per-share trading price to regain or maintain compliance with Nasdaq’s $1.00 minimum bid price requirement after the Company received a Nasdaq deficiency notice, and to avoid the adverse effects of delisting such as reduced liquidity, institutional interest, and impediments to raising capital. The Board’s proposal is structured to give broad discretion to the Board to select the final ratio and timing (up to the 2027 annual meeting) or to abandon the split if it determines it would not be in the Company’s best interests. The proposal would not reduce authorized shares, meaning the number of authorized but unissued shares would increase proportionally post-split, which the Board acknowledges could be used for future issuances and thus have potential dilutive or anti-takeover effects. Management candidly discloses the risks: the reverse split may fail to produce a sustained price improvement, could depress liquidity by reducing shares outstanding, may be perceived negatively by investors, and may not prevent future delisting if other listing standards are not met. The proposal therefore represents a governance trade-off: it grants flexible, unilateral Board authority to act quickly to address listing risk while creating the potential for increased authorized-but-unissued shares and other market-perception downsides. The Board recommends the split as a measured, proactive step to preserve Nasdaq listing and associated strategic benefits, but implementation remains contingent on Board assessment of market conditions and regulatory considerations. Investors evaluating this proposal should weigh the proximate benefit of addressing a $1.00 bid-price deficiency against the long-term strategic implications of increased available share capacity and the uncertain market reaction to reverse splits.

This management-sponsored, non-binding “say-on-pay” proposal asks shareholders to ratify the Company’s executive compensation program as disclosed in the proxy materials. Management frames the program as aligned with stockholder interests and designed to attract, retain, and motivate executives through a mix of base salary, annual performance cash bonuses tied to corporate and individual goals, and long-term equity incentives (options and RSUs) with multi-year vesting schedules. The Compensation Committee, which uses market data and prior consultant input, makes grant and salary decisions and retains discretion over target and actual awards; management indicates it will consider the advisory vote’s outcome when setting future compensation. The proposal is presented in the post-emerging-growth-company context (the company ceased being an EGC as of Dec 31, 2025), making the advisory vote a now-regular shareholder engagement mechanism under Dodd-Frank. As an advisory item, a FOR vote does not bind the Board legally, but a strong negative vote could prompt substantive changes to compensation design, disclosure, or governance practices. Key considerations for an analyst include the alignment of pay with recent performance metrics (noting declining TSR metrics over 2023–2025), the mix between cash and equity, severance/change-in-control protections, and any potential governance issues such as equity pool dilution. Given the Compensation Committee’s rationale and its stated willingness to respond to shareholder feedback, investors should view this vote as a governance signal rather than an operational mandate.

This management proposal asks shareholders to indicate, on a non-binding basis, their preferred frequency for future advisory “say-on-pay” votes, offering one, two, or three-year options. The Board recommends an annual frequency, arguing that annual votes provide the most timely and relevant feedback given that proxy disclosure focuses on compensation granted for the prior fiscal year and because the Board reviews compensation annually. For governance analysts, the vote’s significance lies in signal value: a strong preference by shareholders for triennial or biennial votes could indicate dissatisfaction with the Board’s responsiveness or a desire to reduce proxy costs, while an annual preference suggests shareholders want frequent engagement on pay. Although the result is advisory, the Board has committed to consider the outcome; thus, a divergence between management recommendation and shareholder choice could prompt a formal reassessment of engagement practices. The proposal should be evaluated in the context of the company’s recent pay-for-performance metrics, the degree of shareholder outreach, and whether annual votes have historically led to substantive policy changes at comparable companies. Given the Board’s stated rationale and the alignment with annual compensation review cycles, an annual vote is a reasonable governance default absent specific shareholder objections.

This management proposal seeks shareholder authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies when there are insufficient votes to approve Proposal 3 (the reverse stock split). Functionally, approval grants the Board a procedural tool to postpone a final vote and continue outreach to shareholders, potentially changing the outcome without holding a new separate meeting. The Board frames this as in the best interests of shareholders because it preserves the Company’s ability to obtain approval for the reverse split (intended to address Nasdaq bid-price compliance) without incurring the cost and delay of reconvening or conducting multiple discrete meetings. The governance tradeoffs include the potential perception that management seeks procedural leverage to alter the timing of a substantive shareholder decision, which some investors may view as reducing immediacy of shareholder voice. From an analytical perspective, this proposal should be evaluated in conjunction with Proposal 3: if investors oppose the substantive reverse split, approval of adjournment could be viewed skeptically; if investors are supportive but dispersed, adjournment provides a practical means to aggregate votes to reach a majority. The Board’s recommendation for adjournment indicates a desire to preserve options to address Nasdaq listing risk, but proxy advisors and institutional voters may scrutinize whether management used adequate prior engagement before seeking such authority. Overall, the proposal is a governance-level procedural request whose materiality is contingent on the level of shareholder support for Proposal 3.